Gen-Probe blood-screening assay
This article was originally published in The Gray Sheet
Executive Summary
Firm submits a biologics license application supplement Jan. 29 to run Novartis' Procleix Ultrio blood screening assays for HIV-1 and hepatitis C on its fully automated Tigris system. Ultrio is 510(k)-cleared to screen for those diseases and to detect hepatitis B on the firm's eSAS enhanced semi-automated system. Gen-Probe also plans to begin a postmarket study in March to support an upgrade for Ultrio to screen for hepatitis B on Tigris. FDA originally denied clearance of Ultrio on Tigris in 2005 (1"The Gray Sheet" Oct. 10, 2005, p. 12). Firm also receives a CLIA waiver for its standalone Aptima assay for Chlamydia to test liquid Pap specimens on Tigris...
You may also be interested in...
Gen-Probe Considers Resubmitting 510(k) After FDA Denies Tigris System
Gen-Probe says it will likely re-file a 510(k) for the Procleix Tigris system for use with Chiron's Ultrio assay after the FDA found it "not substantially equivalent" to previously cleared blood screening technology
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.